<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140749</url>
  </required_header>
  <id_info>
    <org_study_id>NL46640.081.14</org_study_id>
    <nct_id>NCT02140749</nct_id>
  </id_info>
  <brief_title>Trial on Short-chain Fructooligosaccharides, Microbiota, and Constipation in Adults</brief_title>
  <acronym>TOMCAT</acronym>
  <official_title>Randomized, Placebo-controlled Double-blind Cross-over Study to Evaluate the Effects of Short-chain Fructooligosaccharides on Stool Frequency in Constipated Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NIZO Food Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ingredion Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NIZO Food Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The dietary short-chain fructooligosaccharides have been shown to increase fecal
      bacterial mass and fermentation metabolites which might stimulate gut motility. Therefore,
      these dietary non-digestible carbohydrates might relieve functional constipation.

      Objective: Study the effect of short-chain fructooligosaccharides on functional constipation.

      Study design: A 16-week, randomized, placebo-controlled, double-blind cross-over trial with
      intervention periods of 4 weeks with a run-in period of 4 weeks and a wash-out period of 4
      weeks.

      Study population: Human subjects with functional constipation according to ROMEIII criteria
      (total n=120; male and female; 18-75 yr).

      Intervention: Placebo and one out of 3 dosages of short-chain fructo-oligosaccharides,
      (Degree of Polymerisation of 3-5; 2, 4 and 8 g/day) for 4 weeks. scFOS will be given as oral
      chews.

      Main study parameters: The primary parameter is the number of complete bowel movements per
      day in subjects with functional constipation according to Rome III criteria. Secondary
      outcomes are Stool consistency (Bristol Stool Scale), Stool frequency, Severity of symptoms
      (Constipation Scoring System; CSS) and Quality of Life (Patient Assessment of Constipation
      Quality of Life; PAC-QoL).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stool frequency (Number of complete bowel movements per day)</measure>
    <time_frame>Change over week 4 and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool consistency (Bristol Stool Scale)</measure>
    <time_frame>Change over week 4 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of symptoms (Constipation Scoring System; CSS)</measure>
    <time_frame>Change over week 4 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Patient Assessment of Constipation Quality of Life; PAC-QoL)</measure>
    <time_frame>Change over week 4 and week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Functional Constipation</condition>
  <arm_group>
    <arm_group_label>sc-FOS 2g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (4 weeks) Short-chain fructooligosaccharide 2 g/day (4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sc-FOS 4g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (4 weeks) Short-chain fructooligosaccharide 4 g/day (4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sc-FOS 8g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (4 weeks) Short-chain fructooligosaccharide 8 g/day (4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sc-FOS 2g/day</intervention_name>
    <description>Chewing tablets containing Short-chain fructooligosaccharides 2g/day</description>
    <arm_group_label>sc-FOS 2g/day</arm_group_label>
    <other_name>FOS</other_name>
    <other_name>Oligofructose</other_name>
    <other_name>scFOS</other_name>
    <other_name>Short-chain fructo-oligosaccharide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sc-FOS 4g/day</intervention_name>
    <description>Chewing tablets containing short-chain Fructooligosaccharides 4g/day</description>
    <arm_group_label>sc-FOS 4g/day</arm_group_label>
    <other_name>FOS</other_name>
    <other_name>Oligofructose</other_name>
    <other_name>scFOS</other_name>
    <other_name>Short-chain fructo-oligosaccharide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sc-FOS 8g/day</intervention_name>
    <description>Chewing tablets containing short-chain Fructooligosaccharides 8g/day</description>
    <arm_group_label>sc-FOS 8g/day</arm_group_label>
    <other_name>FOS</other_name>
    <other_name>Oligofructose</other_name>
    <other_name>scFOS</other_name>
    <other_name>Short-chain fructo-oligosaccharide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Chewing tablets without short-chain Fructooligosaccharides</description>
    <arm_group_label>sc-FOS 2g/day</arm_group_label>
    <arm_group_label>sc-FOS 4g/day</arm_group_label>
    <arm_group_label>sc-FOS 8g/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 yr

          -  Agree to study design (signed informed consent)

          -  At least two of the following symptoms ≥25% of the time with criteria fulfilled for
             the last 3 months with symptom onset at least 6 months prior to inclusion (ROME III
             criteria for functional constipation):

               -  straining, lumpy or hard stool

               -  sensation of incomplete evacuation

               -  sensation of anorectal obstruction ⁄ blockage

               -  use of manual manoeuvres

               -  &lt;3 bowel movements per week

          -  Availability of internet connection

          -  BMI 20-30

          -  Male or female

          -  Willingness to abstain from functional ingredients and such as probiotics, prebiotics
             and foods containing high amounts of fermentable fibers and laxatives starting 1 month
             prior to start of the study as well as during the washout period.

        Exclusion Criteria:

          -  Currently participating in another clinical trial

          -  Drug usage

          -  Excessive alcohol usage (&gt;4 consumptions/day or &gt;20 consumptions/week)

          -  Pregnancy or lactating

          -  Underlying disease of the GI-tract or previous laparotomy, except cholecystectomy and
             appendectomy

          -  Use of antibiotics within 1 month prior to inclusion

          -  Vegetarians

          -  Weight loss &gt; 5 kg within 1 month prior to inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra ten Bruggencate, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIZO Food Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIZO food research</name>
      <address>
        <city>Ede</city>
        <state>Gelderland</state>
        <zip>6718ZB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.nizo.com</url>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bifidobacteria</keyword>
  <keyword>Bristol Stool Scale</keyword>
  <keyword>Constipation</keyword>
  <keyword>Diet</keyword>
  <keyword>Fructooligosacchardes</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Oligofructose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

